Meanwhile, PLK2 binds and phosphorates mutated p53, enhancing its carcinogenic activity; Regulation of PLK2 by wild-type or mutated p53 results in tumor cell growth inhibition or cell proliferation enhancement and chemotherapy resistance respectively; siRNA of mutated p53 or PLK2 improves treatment outcome (116). This evidence concerns the gene TP53 and neoplasm.